CN1239892A - Use of equilenin as antioxidant - Google Patents
Use of equilenin as antioxidant Download PDFInfo
- Publication number
- CN1239892A CN1239892A CN97180448A CN97180448A CN1239892A CN 1239892 A CN1239892 A CN 1239892A CN 97180448 A CN97180448 A CN 97180448A CN 97180448 A CN97180448 A CN 97180448A CN 1239892 A CN1239892 A CN 1239892A
- Authority
- CN
- China
- Prior art keywords
- equilenin
- disease
- salt
- pharmaceutical salts
- free radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 20
- PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 title abstract 2
- PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 150000003254 radicals Chemical class 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- -1 alkali metal salt Chemical class 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 102000004310 Ion Channels Human genes 0.000 claims description 7
- 101710172711 Structural protein Proteins 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000007348 radical reaction Methods 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
- 206010019799 Hepatitis viral Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010038687 Respiratory distress Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001447 alkali salts Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000001862 viral hepatitis Diseases 0.000 claims description 3
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims 2
- 238000005429 filling process Methods 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 23
- 108010007622 LDL Lipoproteins Proteins 0.000 description 23
- 238000007254 oxidation reaction Methods 0.000 description 17
- 230000003647 oxidation Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000010998 test method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 6
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 6
- 150000001993 dienes Chemical class 0.000 description 6
- 229960003399 estrone Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012956 testing procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 150000000307 17β-estradiols Chemical class 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Abstract
This invention provides a method of using equilenin or a pharmaceutically acceptable salt of equilenin-3-sulfate ester as an antioxidant.
Description
Background of invention
The equal congener of free radical of Sheng Chenging and numerous disease biologically, the survival of aerobe in aerobic environment relates to complex interactions (Del Maestro RF between these biologies that have active chemical group generations and their ability of BIOLOGICAL CONTROL, Acta Phy ScanSuppl.492:153-68 (1980)), this interaction between host living beings and the free radical that biologically generates has caused the biochemistry variation of the profundity that damage and death with biological cell is termination.The product of radical reaction accumulation has caused numerous disease, these diseases have been considered to partly result from the interior free radical flux of cell that increases and the cell injury of bringing out, and these diseases include but is not limited to cancer, cardiovascular disease, central nervous system disorder, bone disease, aging, Alzheimers, inflammation, rheumatoid arthritis, autoimmune disease, respiratory distress and emphysema.
Getting in touch of free radical damage and numerous disease widely reported; comprise enzyme; ion channel; many cell component of structural protein and membrane lipid all are potential target (Rice-Evans C of living radical; Mol Aspects of Med 13 (1): 1-111 (1992)); the antioxidant that is in appropriate site can limit this infringement; can influence a series of cell function and cause pathological changes and final cell death with the radical reaction of these potential targets; the antioxidant status that is in the potential reaction site can limit this infringement, and antioxidant is at protection DNA; protein (comprising lipoprotein) and membrane lipid avoid playing an important role in the oxidative damage.
There is strong evidence proof free radical damage to cause many chronic health problems, for most of human diseasess, oxidant by endogenous generation is accessory to initial stage lysis, but oxidative damage has increased the weight of the damage at initial stage, the infringement of organ when for example, reperfusion injury can be defined as showing effect the recovery blood flow after betiding ischemia.Although be essential, the formation of oxygen recovery having increased oxidant in injured tissues has also temporarily worsened this damage, and (UraizeeA, Circulaton 75 (6): 1237-1248 (1987)).Guanieri has described the minimizing lipid peroxidation increase (Biochim-Biophys-ACTA718 (2): 157-164 (1982)) along with reoxygenation then of antioxidant defence in the anoxia cardiac muscle.In reperfusion injury, because adhesion and activate neutrophilic leukocyte, cause producing superoxides after the ischemia in the inflammatory reaction of endothelial injury site.In many different clinical settings, also increased the generation of oxygen-derived free radicals in the liver.In viral hepatitis and chronic active hepatitis, accumulated the macrophage that a large amount of quilts stimulate in the liver, they produce free radical, owing to often increased the generation by the free radical of cytochrome P-450 mediation in the liver, a large amount of deleterious chemical substances cause the hepatogenotoxicity damage.The generation that can conclude the ferrum catalysis hydroxyl that discharges from ferritin is mechanism (Lee WM, the N Eng J of Med that many hepatopathies are easily sent out; Review is (1995) P.1118).
The use of oxidation and antioxidant also is very important for the treatment of many inflammation diseases, and rheumatoid arthritis (RA) is modal chronic inflammatory disease, and epidemiological study shows that standard and clear and definite RA prevalence rate are between 0.3% and 1.5%.Chronic persistence IJD is attended by H in the rheumatoid joint of inflammation
2O
2Generation, during inflammation, polymorphonuclear leukocyte (PMN) and macrophage also especially produce oxygen-derived free radicals.In any chronic or acute inflammation disease, PMN and macrophage can produce O
2 -And H
2O
2Tuberculosis, psoriasis, systemic lupus erythematosus (sle), other autoimmune disease and adult respiratory distress syndrome also can be called as follows the inflammatory diseases of oxidation as principal element, and many other diseases also can be listed in these ranks.
In central nervous system's (CNS) wound and apoplexy (for example ischemia) field, the generation of oxygen-derived free radicals and lipid peroxidation process have also become the focus that research worker is paid close attention to.Many researchs provide a large amount of evidences to prove the reaction ((Hall ED, J-Neurotrauma 9 (Suppl.l): S165-S172 (1992)) that exists free radical and lipid peroxidation in damage or ischemic CNS.
Advised the anti-breast carcinoma of antioxidant protectability and anti-other cancer (comprising the brain cancer and hepatocarcinoma), and protectiveness anti-cardiovascular disease and osteoporosis ((Wiseman H, Free Radical Res21 (3): 187-94 (1994)).Verified these antioxidant protection models and cell membrane (comprising nuclear membrane) are to resist possibility carcinogenic free radical intermediate and lipid peroxidation product.People have concentrated on the attention of the serious syndrome relevant with atherosclerosis and its common sickness rate and can prevent and treat (Steinberg D, N Engl J of Med 14:915-924 (1989)) on this angiopathy by the ability that antioxidant protection low density lipoprotein, LDL (LDL) avoids oxidative damage.
Invention is described
The invention provides the (.+-.)-Equilenin. of antioxidant amounting or its 3-sulfuric ester pharmaceutical salts are fed the mammal that needs with treatment or suppress the method for the disease of free yl induction.Inference according to this, the invention provides and handle free radical and enzyme in the mammal, ion channel, the method of structural protein and membrane lipid reaction, this method comprises (.+-.)-Equilenin. or its medicinal sulfuric acid that feeds as sacrificing substrate, present in an amount at least sufficient to optionally and enzyme with the patient, ion channel, the radical reaction of structural protein and membrane lipid reaction also suppresses free radical and patient's enzyme, ion channel, the reaction of structural protein and membrane lipid wherein determines with the guaranteed concrete disease of antioxidant therapy it is cancer, central nervous system disorder, the bone disease, old and feeble, inflammation, peripheral vascular disease, rheumatoid arthritis, autoimmune disease, respiratory distress, emphysema, prevent perfusion injury again, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus (sle), adult respiratory distress syndrome, central nervous system trauma and apoplexy.
As purposes of the present invention, handle and to comprise existing treatment of diseases, improve disease or palliate a disease, suppress to comprise and suppress or prophylactic development or diffusion.
(.+-.)-Equilenin. 3-sulfuric ester pharmaceutical salts comprises (but being not limited to this) alkali metal salt, alkali salt, ammonium salt, contain the alkylamine salt of 1-6 carbon atom or contain the dialkyl group amine salt of 1-6 carbon atom in alkyl group separately.
The pharmacology method of testing of employing standard is determined the performance of (.+-.)-Equilenin. antioxidant, and this method is measured it to by being exposed to Cu by the free aldehyde (Yagi K., BiochemMed 15:212-216 (1976)) of TBARS (thiobarbituricacid active substance) methods analyst
++The inhibition ability of the formation of the low density lipoprotein, LDL of inductive oxidative deformation (LDL) in ion or the endothelial cells cultured (Parthasarathy S, Proc Natl Acad Sci USA 86:1046-1050 (1989)).
The result who obtains with the pharmacology method of testing of this standard shows that (.+-.)-Equilenin. is effective LDL oxidation reaction inhibitor, promptly suppresses to reach 99%, at Cu
++Obtain the IC of 0.119 μ M and 0.19 μ M in ion mediation and the oxidation mediation of porcine aorta endotheliocyte respectively
50Value.By relatively, in the oxidation method of testing of porcine aorta endotheliocyte mediation, the resulting IC of estrone
50Value is 0.56 μ M.Can prove also that with this method of testing (.+-.)-Equilenin. is effective HDL and blood plasma oxidation retarder, the IC that obtains
50The s value is respectively 0.047 μ M and 0.062 μ M.
The (.+-.)-Equilenin. antioxidant properties is also estimated by its kinetic effect, and this kinetic effect relates at Cu
++There are LDL, the HDL of generation down and the oxidation of blood plasma, promptly have been used to induce standard technique (Esterbauer H, the Ann NY Acad Sci 1989 of LDL degeneration; 570:254-267, Huber LA, Free Rad Res Comms 1990; 8:167-173, VossenRcrm, Lipids 1993; 8:857-861, Jialal I, J Lipid Res1992; 33:899-906).The following parameters of following the tracks of the formation estimation of conjugated diene (main initial stage lipid peroxide) with spectrophotography is: period of delay or T
Min: oxidation begins the used time; T
50: form two used times of diene of 50% conjugation; And T
Max: reach the used time of maximum oxidation.
Concentration is to prolong period of delay 30% during (.+-.)-Equilenin. that 25nM is tried can form in the conjugated diene of human LDL.T
50And T
MaxAll prolong 21%.In same test, the estrone of 25nM only increases all parameter 7-10%.The (.+-.)-Equilenin. of 25nM has the effect of the conjugated diene formation of the human HDL of obvious inhibition, and it prolongs 282% of period of delay.T
50And T
MaxProlong 120% and 105% respectively.The estrone of same concentrations by prolong period of delay 20%, T
5038% and T
MaxThe conjugated diene of 46% couple of HDL forms and works.Prolong period of delay 3% during the (.+-.)-Equilenin. of 25nM can form in the conjugated diene of human plasma, prolong T respectively
50And T
Max21% and 31%, though this has just indicated it to the almost not effect of oxidation initial stage, it has reduced its speed.Estrone in this system is to also not having effect period of delay, for T
50And T
MaxEffect only be respectively 5% and 10%.
For further proving the antioxygenic property of (.+-.)-Equilenin., carry out two additional standard pharmacology testing procedures with cultured cells.In first testing procedure, (.+-.)-Equilenin. exist or non-existent situation under, with the LDL of labelled with radioisotope (
125I-LDL) (McFarlaneAS, In:Munro HN, Allison JB, eds.Mammalian ProteinMetabolism.Vol.l.New York:Academic Press 297-341 (1964)) places Cu
++Middle degeneration.Next step places processing with expressing J774 macrophage in conjunction with the scavenger lipoprotein receptor of oxidative deformation LDL
125Among the I-LDL.This result of the test shows: in the presence of (.+-.)-Equilenin., and the Cu of oxidation
++-the LDL that handles in conjunction with reducing by 60% and 37% (being respectively 2.5 and 0.25 μ M (.+-.)-Equilenin .), by relatively, the estrone of same concentrations reduces the combination of 39% and 0% oxidation LDL respectively.Because the LDL of oxidation is considered to facilitate strongly the growth of spongiocyte and atherosclerotic plaque by macrophage combination and metabolism, therefore, this minimizing LDL oxidation and be attached to subsequently that effect on the scavenger receptor is considered to be highly profitable.
In second testing procedure, (PAEC) places LDL with the porcine aorta endotheliocyte, and this LDL is as above-mentioned by placing the Cu that is with or without under the (.+-.)-Equilenin. situation
++In and degeneration.The LDL that has proved oxidation has cytotoxicity and this process and atherosclerosis to endotheliocyte very strong association.After the LDL incubated cell of handling 24 hours, carry out the MTT test to estimate cytotoxicity (HanSen MB, J Immu Methods 119:203-210 (1989)).This assay method is made an appraisal to the percentage rate of living cells in the give test.In this test, 25 μ g/ml LDL of oxidation when placing no chemical compound to exist in cell, only 2% cell survival gets off afterwards.Contrast with it is placed at cell the Cu under (.+-.)-Equilenin. (the .25 μ M) existence subsequently
++Among the LDL that handles, the percentage rate of survivaling cell is 100% or bigger afterwards.Other chemical compound of testing in identical test is to protection effect minimum (17 beta estradiols=11% survival of PACE; 1,3,5,7-estratetraen-3-ol-17-one=4% survival; Estrone=37% survival).The result of this method of testing proves: there is the LDL no cytotoxicity of modification down in (.+-.)-Equilenin., therefore, these data with above-mentioned by the TBARS method prove consistent by the degeneration of (.+-.)-Equilenin. inhibited oxidation.
The result who obtains based on these method of testings, the pharmaceutical salts of (.+-.)-Equilenin. and its sulfuric ester can be used for treating or suppressing the disease of free yl induction as antioxidant, described pharmaceutical salts such as alkali metal salt, alkali salt, ammonium salt, contains the alkylamine salt of 1-6 carbon atom or contain the dialkyl group amine salt of 1-6 carbon atom in alkyl group separately.
Antioxidant of the present invention can be mixed with pure or prepare administration with pharmaceutical carrier, and the route of administration of dissolubility by chemical compound and chemical property, selection and the pharmacology of standard put into practice to determine the ratio of carrier.Pharmaceutical carrier can be solid or liquid.
Solid carrier can comprise one or more materials, and this material also can play correctives, lubricant, solubilizing agent, suspending agent, filler, fluidizer, compression aid, binding agent or tablet disintegrant; Solid carrier also can be the encapsulate material.In powder, carrier is the solid of segmentation, and this solid mixes with the active component of segmentation.In tablet, active component and the carrier with required compression property are with suitable mixed and be pressed into required shape and size.Preferred powder and tablet contain to the active component that reaches 99%.Suitable solid carrier comprises calcium phosphate, magnesium stearate, Talcum, sucrose, lactose, dextrin, starch, gelatin, cellulose, methylcellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melt wax and ion exchange resin.
Liquid-carrier is used to prepare solution, suspension, Emulsion, syrup, elixir and pressurized compositions.Active component can be dissolved in or be suspended in the medicinal fluid carrier, in water, organic solvent, both mixture or medicinal oil or fat, liquid-carrier can contain other suitable medical additive, as solubilizing agent, emulsifying agent, buffer, antiseptic, sweeting agent, correctives, suspending agent, thickening agent, pigment, viscosity-controlling agent, stabilizing agent or Osmolyte regulator.Oral and the suitable example of liquid-carrier parenteral comprises that water (partly contains additive as above, as cellulose derivative, the preferably carboxymethyl cellulose sodium solution), alcohol (comprising MHA and polyhydroxy-alcohol) and their derivant, lethicins and oil (as the Oleum Cocois and the Oleum Arachidis hypogaeae semen of rectification) as ethylene glycol.For parenteral, carrier also can be an oils and fats, as ethyl oleate and Semen Myristicae isopropyl acid ester.The sterile liquid carrier is used for the compositions of the sterile liquid form of parenteral, can be halogenated hydrocarbon or other medicinal propellant for the liquid-carrier of pressurized compositions.
The composition of liquid medicine of sterile solution or suspension can use by for example intramuscular, intraperitoneal or subcutaneous injection.Sterile solution also can intravenously administrable, and chemical compound of the present invention also can be with the form oral administration of liquid or solid compositions.
Antioxidant of the present invention can conventional suppository the form per rectum feed, for by sucking or be blown into administration in intranasal or the bronchus, antioxidant of the present invention can be mixed with aqueous solution or partially aqueous solution, it can be used with the form of aerosol, The compounds of this invention also can feed by the transdermal sheet percutaneous that contains reactive compound and carrier, described carrier for reactive compound be inert, for skin be nontoxic, and can the medicament general of transmission be adsorbed onto in the blood flow by skin.Carrier can be taked various ways, as cream and ointment, paste, gel and closing device.Cream and ointment can be the thick liquid or the semisolid Emulsion of oil-in-water type or water-in-oil type, and the paste that dispersive adsorptivity powder is formed in oil that contains active component or hydrophilic petroleum also is suitable for.Also can utilize multiple closing device that active component is discharged in the blood flow, contain active component, have or the semipermeable membrane of DNAcarrier free reservoir or contain the substrate of active component as covering, other closing device sees in the document.
In addition, by being mixed with the preparation that contains 0.1-5% (preferred 2%) reactive compound with pharmaceutical excipient, antioxidant of the present invention can be used as solution, cream or washing liquid and uses the zone that imposes on the fungus effect.
The concrete object that required dosage is treated with used concrete compositions, route of administration, the seriousness that presents symptom and quilt changes, the result who obtains based on standard pharmacology method of testing, the daily dose of the reactive compound of design should be 0.02 μ g/kg-500 μ g/kg, by the low dose of begin treatment with the optimal dose that is less than chemical compound.Then, increase dosage to the optimum efficiency that reaches under the treatment environment; The pharmacists can determine the exact dose of oral, parenteral, intranasal or intraperitoneal administration according to the experience of each object of treatment, preferred pharmaceutical compositions is a unit dosage form, for example, and tablet or capsule, in this form, compositions is subdivided into the unit dose that contains the appropriate amount active component; Unit dosage forms can be packaged compositions, for example, is packaged powder, can be medicine bottle, ampoule, pre-filled syringe or the sachets that contains liquid.Unit dosage form can be for example capsule or tablet itself, maybe can be any described compositions of suitable quantity under the packaged form.
Claims (4)
1. suppress or treat the method for the disease of free yl induction, this method is for to be used for the mammal of needs with the (.+-.)-Equilenin. of antioxidant amounting or the pharmaceutical salts of (.+-.)-Equilenin .-3-sulfuric ester.
2. the process of claim 1 wherein that the pharmaceutical salts of (.+-.)-Equilenin .-3-sulfuric ester is alkali metal salt, alkali salt, ammonium salt, contains the alkylamine salt of 1-6 carbon atom or contain the dialkyl group amine salt of 1-6 carbon atom in each alkyl group.
3. need to suppress the method that free radical and enzyme, ion channel, structural protein and membrane lipid react in the mammal of corresponding treatment, this method comprises to be used as the (.+-.)-Equilenin. of sacrificing substrate or the pharmaceutical salts of (.+-.)-Equilenin .-3-sulfuric ester, present in an amount at least sufficient to optionally with the radical reaction of enzyme, ion channel, structural protein and the membrane lipid reaction of described mammal and suppress free radical and the reaction of the enzyme of described mammal, ion channel, structural protein and membrane lipid.
4. the method that suppresses the endogenous free radical relevant with following advancing of disease, described disease is a cancer, central nervous system disorder, Alzheimer, the bone disease, old and feeble, inflammation, peripheral vascular disease, rheumatoid arthritis, autoimmune disease, respiratory distress, emphysema, prevent perfusion injury again, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus (sle), adult respiratory distress syndrome, central nervous system trauma and apoplexy, or the damage in filling process again, this method comprises the pharmaceutical salts of using (.+-.)-Equilenin. or (.+-.)-Equilenin .-3-sulfuric ester.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76257996A | 1996-12-10 | 1996-12-10 | |
US08/762,579 | 1996-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1239892A true CN1239892A (en) | 1999-12-29 |
Family
ID=25065472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97180448A Pending CN1239892A (en) | 1996-12-10 | 1997-12-05 | Use of equilenin as antioxidant |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0944391A1 (en) |
JP (1) | JP2001506628A (en) |
KR (1) | KR20000069412A (en) |
CN (1) | CN1239892A (en) |
AR (1) | AR010344A1 (en) |
AU (1) | AU743586B2 (en) |
BR (1) | BR9714384A (en) |
CA (1) | CA2272087A1 (en) |
HU (1) | HUP0000569A3 (en) |
IL (1) | IL130071A0 (en) |
NZ (1) | NZ336343A (en) |
TW (1) | TW466115B (en) |
WO (1) | WO1998025626A1 (en) |
ZA (1) | ZA9711052B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271221B1 (en) * | 1996-12-10 | 2001-08-07 | American Home Products Corporation | Use of equilenin as an antioxidant |
DE19915576A1 (en) | 1999-03-30 | 2000-10-05 | Jenapharm Gmbh | New equilenine derivatives, useful as antioxidative estrogenic hormonal steroids for e.g. prophylactic geriatrics in women and men |
CA2466928A1 (en) * | 2001-12-10 | 2003-07-03 | Yansheng Du | Treatment of neurodegenerative and cardiovascular disorders |
CN108958639B (en) | 2017-05-19 | 2021-07-06 | 华邦电子股份有限公司 | Flash memory storage device |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4154820A (en) * | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
EP0240717A3 (en) * | 1986-03-04 | 1990-05-16 | Board of Regents of the University of Nebraska | Prevention of mammary carcinoma |
US4937238A (en) * | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
US5545635A (en) * | 1995-05-23 | 1996-08-13 | Eli Lilly And Company | Inhibiting bone loss with equilenin |
-
1997
- 1997-11-27 TW TW086117838A patent/TW466115B/en not_active IP Right Cessation
- 1997-12-05 JP JP52680498A patent/JP2001506628A/en not_active Ceased
- 1997-12-05 NZ NZ336343A patent/NZ336343A/en unknown
- 1997-12-05 WO PCT/US1997/022154 patent/WO1998025626A1/en not_active Application Discontinuation
- 1997-12-05 CA CA002272087A patent/CA2272087A1/en not_active Abandoned
- 1997-12-05 KR KR1019997005181A patent/KR20000069412A/en not_active Application Discontinuation
- 1997-12-05 IL IL13007197A patent/IL130071A0/en unknown
- 1997-12-05 AU AU53707/98A patent/AU743586B2/en not_active Ceased
- 1997-12-05 CN CN97180448A patent/CN1239892A/en active Pending
- 1997-12-05 HU HU0000569A patent/HUP0000569A3/en unknown
- 1997-12-05 EP EP97950808A patent/EP0944391A1/en not_active Withdrawn
- 1997-12-05 BR BR9714384-7A patent/BR9714384A/en not_active IP Right Cessation
- 1997-12-09 ZA ZA9711052A patent/ZA9711052B/en unknown
- 1997-12-09 AR ARP970105778A patent/AR010344A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR9714384A (en) | 2000-05-16 |
ZA9711052B (en) | 1999-06-09 |
CA2272087A1 (en) | 1998-06-18 |
NZ336343A (en) | 2000-11-24 |
KR20000069412A (en) | 2000-11-25 |
TW466115B (en) | 2001-12-01 |
WO1998025626A1 (en) | 1998-06-18 |
HUP0000569A3 (en) | 2000-11-28 |
JP2001506628A (en) | 2001-05-22 |
AU5370798A (en) | 1998-07-03 |
HUP0000569A2 (en) | 2000-10-28 |
AR010344A1 (en) | 2000-06-07 |
IL130071A0 (en) | 2000-02-29 |
AU743586B2 (en) | 2002-01-31 |
EP0944391A1 (en) | 1999-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5869090A (en) | Transdermal delivery of dehydroepiandrosterone | |
US5798348A (en) | Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight | |
EP0904064A1 (en) | Oral pharmaceutical compositions containing sex hormones | |
US5709878A (en) | Transdermal delivery of dehydroepiandrosterone | |
JP2003514886A (en) | Nervonic acid derivatives, their preparation and use | |
HUE027298T2 (en) | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties | |
CN109310676A (en) | The pharmaceutical composition of a kind of phenol derivatives and Etomidate, pharmaceutical preparation and application thereof | |
CN1239892A (en) | Use of equilenin as antioxidant | |
CN1239890A (en) | 17 'alpha'-dihydroequilenin for use as medical antioxidant | |
CN1104900C (en) | Use of 8,9-dehydroestrone as antioxidant | |
JPH03294230A (en) | Remedy for endometritis | |
KR100343272B1 (en) | Pharmaceutical emulsions containing bioactive steroids | |
CN1239891A (en) | Use of 17 '-dihydroequilenin as an antioxidant | |
EP0850647B1 (en) | Application of 11-substituted steroids for the preparation of medicaments with dissociated estrogenic activity | |
US6271221B1 (en) | Use of equilenin as an antioxidant | |
MXPA96006009A (en) | Use of 8,9-dehydroestrone as an antioxide | |
JP2002534469A (en) | Use of estrogens and delta-gonadien-21-ol-3,20-dione | |
JPH0899879A (en) | Dermatological medicine containing content of fatty acid glyceride again heavy infection | |
JPH08208428A (en) | Composition for dermatology to heavy infection containing fatty acid and fatty acid glyceride | |
JP2999539B2 (en) | Prevention and treatment of leukopenia | |
JPH10279483A (en) | Agent for increasing bone density |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |